메뉴 건너뛰기




Volumn 92, Issue 8, 2017, Pages E146-E152

Daratumumab monotherapy compared with historical control data in heavily pretreated and highly refractory patients with multiple myeloma: An adjusted treatment comparison

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; BENDAMUSTINE; BORTEZOMIB; CARFILZOMIB; CYTOTOXIC AGENT; DARATUMUMAB; HEMOGLOBIN; LENALIDOMIDE; POMALIDOMIDE; THALIDOMIDE; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

EID: 85022338705     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.24781     Document Type: Article
Times cited : (28)

References (22)
  • 1
    • 84995370793 scopus 로고    scopus 로고
    • Analysis of real-world data on overall survival in multiple myeloma patients with ≥3 prior lines of therapy including a proteasome inhibitor (PI) and an immunomodulatory drug (IMiD), or double refractory to a PI and an IMiD
    • Usmani S, Ahmadi T, Ng Y, et al. Analysis of real-world data on overall survival in multiple myeloma patients with ≥3 prior lines of therapy including a proteasome inhibitor (PI) and an immunomodulatory drug (IMiD), or double refractory to a PI and an IMiD. Oncologist. 2016;21:1355–1361.
    • (2016) Oncologist. , vol.21 , pp. 1355-1361
    • Usmani, S.1    Ahmadi, T.2    Ng, Y.3
  • 2
    • 1642348370 scopus 로고    scopus 로고
    • Flow cytometric immunophenotypic analysis of 306 cases of multiple myeloma
    • Lin P, Owens R, Tricot G, Wilson CS. Flow cytometric immunophenotypic analysis of 306 cases of multiple myeloma. Am J Clin Pathol. 2004;121:482–488.
    • (2004) Am J Clin Pathol. , vol.121 , pp. 482-488
    • Lin, P.1    Owens, R.2    Tricot, G.3    Wilson, C.S.4
  • 3
    • 1842611807 scopus 로고    scopus 로고
    • + B-lymphocytes in bone marrow, peripheral blood and PBSC harvest in multiple myeloma patients
    • + B-lymphocytes in bone marrow, peripheral blood and PBSC harvest in multiple myeloma patients. Leuk Res. 2004;28:469–477.
    • (2004) Leuk Res. , vol.28 , pp. 469-477
    • Santonocito, A.M.1    Consoli, U.2    Bagnato, S.3
  • 4
    • 0035177850 scopus 로고    scopus 로고
    • Human CD38: a (r)evolutionary story of enzymes and receptors
    • Deaglio S, Mehta K, Malavasi F. Human CD38: a (r)evolutionary story of enzymes and receptors. Leuk Res. 2001;25:1–12.
    • (2001) Leuk Res. , vol.25 , pp. 1-12
    • Deaglio, S.1    Mehta, K.2    Malavasi, F.3
  • 5
    • 79251570884 scopus 로고    scopus 로고
    • Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors
    • de Weers M, Tai YT, van der Veer MS, et al. Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors. J Immunol. 2011;186:1840–1848.
    • (2011) J Immunol. , vol.186 , pp. 1840-1848
    • de Weers, M.1    Tai, Y.T.2    van der Veer, M.S.3
  • 6
    • 84924546237 scopus 로고    scopus 로고
    • Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma
    • Overdijk MB, Verploegen S, Bogels M, et al. Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma. MAbs. 2015;7:311–321.
    • (2015) MAbs. , vol.7 , pp. 311-321
    • Overdijk, M.B.1    Verploegen, S.2    Bogels, M.3
  • 7
    • 85022333309 scopus 로고    scopus 로고
    • Direct in vitro comparison of daratumumab with surrogate analogs of CD38 antibodies MOR03087, SAR650984 and Ab79. 56th ASH, Annual Meeting and Exposition; December 6–9, 2014; San Francisco, CA
    • ® Annual Meeting and Exposition; December 6–9, 2014; San Francisco, CA 2014. Abstract 3474.
    • (2014)
    • Lammerts van Bueren, J.1    Jakobs, D.2    Kaldenhoven, N.3
  • 8
    • 84979518325 scopus 로고    scopus 로고
    • The therapeutic CD38 monoclonal antibody daratumumab induces programmed cell death via Fc? receptor-mediated cross-linking
    • Overdijk MB, Jansen JH, Nederend M, et al. The therapeutic CD38 monoclonal antibody daratumumab induces programmed cell death via Fc? receptor-mediated cross-linking. J Immunol. 2016;197:807–813.
    • (2016) J Immunol , vol.197 , pp. 807-813
    • Overdijk, M.B.1    Jansen, J.H.2    Nederend, M.3
  • 9
    • 84979519854 scopus 로고    scopus 로고
    • + immune-regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma
    • + immune-regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma. Blood. 2016;128:384–394.
    • (2016) Blood. , vol.128 , pp. 384-394
    • Krejcik, J.1    Casneuf, T.2    Nijhof, I.S.3
  • 10
    • 84977616350 scopus 로고    scopus 로고
    • Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma
    • Usmani SZ, Weiss BM, Plesner T, et al. Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma. Blood. 2016;128:37–44.
    • (2016) Blood. , vol.128 , pp. 37-44
    • Usmani, S.Z.1    Weiss, B.M.2    Plesner, T.3
  • 11
    • 84954377172 scopus 로고    scopus 로고
    • Daratumumab: first global approval
    • McKeage K. Daratumumab: first global approval. Drugs. 2016;76:275–281.
    • (2016) Drugs. , vol.76 , pp. 275-281
    • McKeage, K.1
  • 12
    • 85022339957 scopus 로고    scopus 로고
    • EPAR summary for the public. Darzalex daratumumab., Accessed December 21
    • European Medicines Agency. EPAR summary for the public. Darzalex daratumumab. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Summary_for_the_public/human/004077/WC500207298.pdf. Accessed December 21, 2016.
    • (2016)
  • 14
    • 84942436321 scopus 로고    scopus 로고
    • Targeting CD38 with daratumumab monotherapy in multiple myeloma
    • Lokhorst HM, Plesner T, Laubach JP, et al. Targeting CD38 with daratumumab monotherapy in multiple myeloma. N Engl J Med. 2015;373:1207–1219.
    • (2015) N Engl J Med. , vol.373 , pp. 1207-1219
    • Lokhorst, H.M.1    Plesner, T.2    Laubach, J.P.3
  • 15
    • 84953325096 scopus 로고    scopus 로고
    • Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial
    • Lonial S, Weiss B, Usmani S, et al. Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial. Lancet. 2016;387:1551–1560.
    • (2016) Lancet. , vol.387 , pp. 1551-1560
    • Lonial, S.1    Weiss, B.2    Usmani, S.3
  • 16
    • 84892372742 scopus 로고
    • The robust inference for the proportional hazards model
    • Lin DY, Wei LJ. The robust inference for the proportional hazards model. J Am Stat Assoc. 1989;84:1074–1078.
    • (1989) J Am Stat Assoc. , vol.84 , pp. 1074-1078
    • Lin, D.Y.1    Wei, L.J.2
  • 18
    • 79952911779 scopus 로고    scopus 로고
    • Ten years of improvement in the management of multiple myeloma: 2000–2010
    • Harousseau JL. Ten years of improvement in the management of multiple myeloma: 2000–2010. Clin Lymphoma Myeloma Leuk. 2010;10:424–442.
    • (2010) Clin Lymphoma Myeloma Leuk. , vol.10 , pp. 424-442
    • Harousseau, J.L.1
  • 19
    • 41949130070 scopus 로고    scopus 로고
    • Improved survival in multiple myeloma and the impact of novel therapies
    • Kumar SK, Rajkumar SV, Dispenzieri A, et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood. 2008;111:2516–2520.
    • (2008) Blood. , vol.111 , pp. 2516-2520
    • Kumar, S.K.1    Rajkumar, S.V.2    Dispenzieri, A.3
  • 20
    • 67349240834 scopus 로고    scopus 로고
    • Improved survival of patients with multiple myeloma after the introduction of novel agents and the applicability of the International Staging System (ISS): an analysis of the Greek Myeloma Study Group (GMSG)
    • Kastritis E, Zervas K, Symeonidis A, et al. Improved survival of patients with multiple myeloma after the introduction of novel agents and the applicability of the International Staging System (ISS): an analysis of the Greek Myeloma Study Group (GMSG). Leukemia. 2009;23:1152–1157.
    • (2009) Leukemia. , vol.23 , pp. 1152-1157
    • Kastritis, E.1    Zervas, K.2    Symeonidis, A.3
  • 21
    • 84856719479 scopus 로고    scopus 로고
    • Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study
    • Kumar SK, Lee JH, Lahuerta JJ, et al. Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study. Leukemia. 2012;26:149–157.
    • (2012) Leukemia. , vol.26 , pp. 149-157
    • Kumar, S.K.1    Lee, J.H.2    Lahuerta, J.J.3
  • 22
    • 85022331480 scopus 로고    scopus 로고
    • Adjusted comparisons suggest daratumumab is associated with prolonged survival compared with standard of care therapies in patients with heavily pre-treated and highly refractory multiple myeloma. Poster presented at the 58th American Society of Hematology Annual Meeting & Exposition, San Diego, CA, December 3–6
    • Kumar S, Durie B, Su Z, et al. Adjusted comparisons suggest daratumumab is associated with prolonged survival compared with standard of care therapies in patients with heavily pre-treated and highly refractory multiple myeloma. Poster presented at the 58th American Society of Hematology Annual Meeting & Exposition, San Diego, CA, December 3–6, 2016.
    • (2016)
    • Kumar, S.1    Durie, B.2    Su, Z.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.